Keyphrases
Tolerability
100%
Chronic Myeloid Leukemia
100%
Imatinib
100%
Imatinib Therapy
100%
Retrospective Research
100%
Response Monitoring
100%
Response Effectiveness
100%
Molecular Diagnostics
50%
Cytogenetic Assay
50%
Adverse Drug Events
37%
Chronic Phase
25%
Clinical Trials
12%
Electronic Health Records
12%
Retrospective Review
12%
Suboptimal Response
12%
Dasatinib
12%
Current Management
12%
Overall Survival
12%
Dose Reduction
12%
Nineteen
12%
Overall Survival Rate
12%
Treatment Failure
12%
Received Dose
12%
Nilotinib
12%
Complete Cytogenetic Response
12%
Suboptimal Treatment
12%
Experiential Outcomes
12%
Therapy Modification
12%
Dose Increase
12%
Major Molecular Response
12%
Valuable Insight
12%
Pharmacology, Toxicology and Pharmaceutical Science
Tolerability
100%
Chronic Myeloid Leukemia
100%
Imatinib
100%
Adverse Drug Reaction
33%
Overall Survival
22%
Clinical Trial
11%
Survival Rate
11%
Dasatinib
11%
Nilotinib
11%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Imatinib
100%
Cytogenetics
55%
Overall Survival
22%
Clinical Trial
11%
Survival Rate
11%
Electronic Health Record
11%
Drug Dose Reduction
11%
Drug Dose Increase
11%
Dasatinib
11%
Nilotinib
11%